Overview

Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients

Status:
Completed

Trial end date:
2015-03-01

Target enrollment:

Participant gender:

Summary

This study will explore the relationship of different DEB025 doses in combination with RBV to pharmacokinetic, pharmacodynamic (i.e. viral load reduction) and safety profiles in chronic hepatitis C GT 2 and 3 treatment naïve patients.

Phase:

N/A

Details

Lead Sponsor:

Debiopharm International SA

Treatments:

Interferon-alpha
Peginterferon alfa-2a
Ribavirin